- Browse by Author
Browsing by Author "ALShakhs, Fatemah M."
Now showing 1 - 2 of 2
Results Per Page
Sort Options
Item Colorectal cancer in patients with SARS-CoV-2: a systematic review and meta-analysis(BMC, 2022-09-12) Alhumaid, Saad; Al Mutair, Abbas; Busubaih, Jawad S.; Al Dossary, Nourah; Alsuliman, Murtadha; Baltyour, Sarah A.; Alissa, Ibrahim; Al Hassar, Hassan I.; Al Aithan, Noor A.; Albassri, Hani A.; AlOmran, Suliman A.; ALGhazal, Raed M.; Busbaih, Ahmed; Alsalem, Nasser A.; Alagnam, Waseem; Alyousef, Mohammed Y.; Alseffay, Abdulaziz U.; Al Aish, Hussain A.; Aldiaram, Ali; Al Eissa, Hisham A.; Alhumaid, Murtadha A.; Bukhamseen, Ali N.; Al Mutared, Koblan M.; Aljwisim, Abdullah H.; Twibah, Abdullah M.; AlSaeed, Meteab M.; Alkhalaf, Hussien A.; ALShakhs, Fatemah M.; Koritala, Thoyaja; Al-Tawfiq, Jaffar A.; Dhama, Kuldeep; Rabaan, Ali A.; Al-Omari, Awad; Medicine, School of MedicineBackground: Patients with colorectal cancer (CRC) are more likely to develop severe course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and experience increased risk of mortality compared to SARS-CoV-2 patients without CRC. Objectives: To estimate the prevalence of SARS-CoV-2 infection in CRC patients and analyse the demographic parameters, clinical characteristics and treatment outcomes in CRC patients with COVID-19 illness. Methods: For this systematic review and meta-analysis, we searched Proquest, Medline, Embase, Pubmed, CINAHL, Wiley online library, Scopus and Nature for studies on the incidence of SARS-CoV-2 infection in CRC patients, published from December 1, 2019 to December 31, 2021, with English language restriction. Effect sizes of prevalence were pooled with 95% confidence intervals (CIs). Sub-group analyses were performed to minimize heterogeneity. Binary logistic regression model was used to explore the effect of various demographic and clinical characteristics on patient's final treatment outcome (survival or death). Results: Of the 472 papers that were identified, 69 articles were included in the systematic review and meta-analysis (41 cohort, 16 case-report, 9 case-series, 2 cross-sectional, and 1 case-control studies). Studies involving 3362 CRC patients with confirmed SARS-CoV-2 (all patients were adults) were analyzed. The overall pooled proportions of CRC patients who had laboratory-confirmed community-acquired and hospital-acquired SARS-CoV-2 infections were 8.1% (95% CI 6.1 to 10.1, n = 1308, 24 studies, I2 98%, p = 0.66), and 1.5% (95% CI 1.1 to 1.9, n = 472, 27 studies, I2 94%, p < 0.01). The median patient age ranged from 51.6 years to 80 years across studies. The majority of the patients were male (n = 2243, 66.7%) and belonged to White (Caucasian) (n = 262, 7.8%), Hispanic (n = 156, 4.6%) and Asian (n = 153, 4.4%) ethnicity. The main source of SARS-CoV-2 infection in CRC patients was community-acquired (n = 2882, 85.7%; p = 0.014). Most of those SARS-CoV-2 patients had stage III CRC (n = 725, 21.6%; p = 0.036) and were treated mainly with surgical resections (n = 304, 9%) and chemotherapies (n = 187, 5.6%), p = 0.008. The odd ratios of death were significantly high in patients with old age (≥ 60 years) (OR 1.96, 95% CI 0.94-0.96; p < 0.001), male gender (OR 1.44, 95% CI 0.41-0.47; p < 0.001) CRC stage III (OR 1.54, 95% CI 0.02-1.05; p = 0.041), CRC stage IV (OR 1.69, 95% CI 0.17-1.2; p = 0.009), recent active treatment with chemotherapies (OR 1.35, 95% CI 0.5-0.66; p = 0.023) or surgical resections (OR 1.4, 95% CI 0.8-0.73; p = 0.016) and admission to ICU (OR 1.88, 95% CI 0.85-1.12; p < 0.001) compared to those who survived. Conclusion: SARS-CoV-2 infection in CRC patient is not uncommon and results in a mortality rate of 26.2%. Key determinants that lead to increased mortality in CRC patients infected with COVID-19 include older age (≥ 60 years old); male gender; Asian and Hispanic ethnicity; if SARS-CoV-2 was acquired from hospital source; advanced CRC (stage III and IV); if patient received chemotherapies or surgical treatment; and if patient was admitted to ICU, ventilated or experienced ARDS.Item New-onset and relapsed liver diseases following COVID-19 vaccination: a systematic review(BMC, 2022-10-13) Alhumaid, Saad; Al Mutair, Abbas; Rabaan, Ali A.; ALShakhs, Fatemah M.; Choudhary, Om Prakash; Yong, Shin Jie; Nainu, Firzan; Khan, Amjad; Muhammad, Javed; Alhelal, Fadil; Al Khamees, Mohammed Hussain; Alsouaib, Hussain Ahmed; Al Majhad, Ahmed Salman; Al-Tarfi, Hassan Redha; ALyasin, Ali Hussain; Alatiyyah, Yaqoub Yousef; Alsultan, Ali Ahmed; Alessa, Mohammed Essa; Alessa, Mustafa Essa; Alissa, Mohammed Ahmed; Alsayegh, Emad Hassan; Alshakhs, Hassan N.; Al Samaeel, Haidar Abdullah; AlShayeb, Rugayah Ahmed; Alnami, Dalal Ahmed; Alhassan, Hussain Ali; Alabdullah, Abdulaziz Abdullah; Alhmed, Ayat Hussain; AlDera, Faisal Hussain; Hajissa, Khalid; Al-Tawfiq, Jaffar A.; Al-Omari, Awad; Medicine, School of MedicineBackground: Liver diseases post-COVID-19 vaccination is extremely rare but can occur. A growing body of evidence has indicated that portal vein thrombosis, autoimmune hepatitis, raised liver enzymes and liver injuries, etc., may be potential consequence of COVID-19 vaccines. Objectives: To describe the results of a systematic review for new-onset and relapsed liver disease following COVID-19 vaccination. Methods: For this systematic review, we searched Proquest, Medline, Embase, PubMed, CINAHL, Wiley online library, Scopus and Nature through the Preferred Reporting Items for Systematic Reviews and Meta Analyses PRISMA guideline for studies on the incidence of new onset or relapsed liver diseases post-COVID-19 vaccination, published from December 1, 2020 to July 31, 2022, with English language restriction. Results: Two hundred seventy-five cases from one hundred and eighteen articles were included in the qualitative synthesis of this systematic review. Autoimmune hepatitis (138 cases) was the most frequent pathology observed post-COVID-19 vaccination, followed by portal vein thrombosis (52 cases), raised liver enzymes (26 cases) and liver injury (21 cases). Other cases include splanchnic vein thrombosis, acute cellular rejection of the liver, jaundice, hepatomegaly, acute hepatic failure and hepatic porphyria. Mortality was reported in any of the included cases for acute hepatic failure (n = 4, 50%), portal vein thrombosis (n = 25, 48.1%), splanchnic vein thrombosis (n = 6, 42.8%), jaundice (n = 1, 12.5%), raised liver enzymes (n = 2, 7.7%), and autoimmune hepatitis (n = 3, 2.2%). Most patients were easily treated without any serious complications, recovered and did not require long-term hepatic therapy. Conclusion: Reported evidence of liver diseases post-COIVD-19 vaccination should not discourage vaccination against this worldwide pandemic. The number of reported cases is relatively very small in relation to the hundreds of millions of vaccinations that have occurred and the protective benefits offered by COVID-19 vaccination far outweigh the risks.